Protocol for the MPTP mouse model of Parkinson's disease

  title={Protocol for the MPTP mouse model of Parkinson's disease},
  author={Vernice R. Jackson-Lewis and Serge Przedborski},
  journal={Nature Protocols},
This protocol describes our method of producing a reliable mouse model of Parkinson's disease (PD) using the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). We discuss the particulars of the model, provide key references and outline what investigators need to know to develop the MPTP mouse model of PD safely and successfully. Completion of this protocol depends on the regimen of MPTP used and on the actual planned studies, which often range from 7 to 30 d. This protocol calls… 

MPTP mouse models of Parkinson's disease: an update.

The ability of MPTP mouse models to replicate the pathophysiology of PD, the mechanisms ofMPTP-induced neurotoxicity, strain differences in susceptibility to MPTP, and the models' roles in testing therapeutic approaches are discussed.

Generation of Mitochondrial Toxin Rodent Models of Parkinson's Disease Using 6-OHDA , MPTP , and Rotenone.

This chapter describes the preparation of these mitochondrial toxin models of Parkinson's disease using 6-hydroxydopamine, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, and rotenone.

Behavior, PET and histology in novel regimen of MPTP marmoset model of Parkinson’s disease for long-term stem cell therapy

A low-dose MPTP regimen protocol was found to be stable parkinsonism without mortality as evidenced by behavior, PET, and TH immunohistochemistry and will be useful for evaluation of possible long-term stem cell therapy for anti-parkinsonian activity.

MPTP-induced mouse model of Parkinson’s disease: A promising direction for therapeutic strategies

The role of MPTP in producing Parkinson-like symptoms in mice and the experimental role of the MPTP-induced mouse model are summarized.

Neurotoxin-based models of Parkinson's disease

Dynamic Changes in the Nigrostriatal Pathway in the MPTP Mouse Model of Parkinson's Disease

An overview of the dynamic changes in the nigrostriatal pathway in the MPTP mouse model of PD is provided to assist with the development of interventions or therapeutic strategies for PD.



Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse.

It is clear that the MPTP-treated mouse is a good model for Parkinson's disease and may help to define the role of dopamine deficiency in the pathophysiology of Parkinson’s disease as well as provide a model in which potential anti-Parkinsonian therapeutic agents can be tested.

Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease

It is shown that after administration of MPTP to mice, there was a robust gliosis in the substantia nigra pars compacta associated with significant upregulation of inducible nitric oxide synthase (iNOS), which indicates that inhibitors of iNOS may provide protective benefit in the treatment of Parkinson disease.

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.

It is proposed that this chemical selectively damages cells in the substantia nigra in patients who developed marked parkinsonism after using an illicit drug intravenously.

Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein.

Continuous low-level exposure of mice to MPTP causes a Parkinson-like syndrome in an alpha-synuclein-dependent manner, and the inhibition of the ubiquitinproteasome system and the production of inclusion bodies were reduced.

The parkinsonian toxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP): a technical review of its utility and safety

The purpose of this review is to inform the researcher of the hazardous nature of MPTP and to provide guidance for its safe handling and use.

Recommended safe practices for using the neurotoxin MPTP in animal experiments.

Proper procedures to minimize contact with animal fur, bedding and excreta should protect investigators working with MPTP over extended periods.

The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice.

Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease

It is shown that the pro-apoptotic protein Bax is highly expressed in the SNpc and that its ablation attenuates SNpc developmental neuronal apoptosis, and it is suggested that targeting Bax may provide protective benefit in the treatment of Parkinson's disease.

Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration.

It is concluded that nigrostriatal dopaminergic neurons in the rat require exposure to a much higher concentration of MPP+ than do those in mice for the induction of toxicity.